NasdaqGS - Delayed Quote USD

Atara Biotherapeutics, Inc. (ATRA)

0.6400 +0.0350 (+5.79%)
At close: May 15 at 4:00 PM EDT
0.6700 +0.03 (+4.69%)
After hours: May 15 at 7:58 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
34,704.0000
8,573.0000
63,573.0000
20,340.0000
--
Cost of Revenue
10,655.0000
8,886.0000
--
--
--
Gross Profit
24,049.0000
-313.0000
63,573.0000
--
--
Operating Expense
256,284.0000
275,693.0000
344,086.0000
360,802.0000
309,052.0000
Operating Income
-232,235.0000
-276,006.0000
-280,513.0000
-340,462.0000
-309,052.0000
Net Non Operating Interest Income Expense
-874.0000
141.0000
2,686.0000
367.0000
2,447.0000
Other Income Expense
19.0000
-246.0000
49,537.0000
--
--
Pretax Income
-233,090.0000
-276,111.0000
-228,290.0000
-340,095.0000
-306,605.0000
Tax Provision
17.0000
15.0000
12.0000
46.0000
15.0000
Net Income Common Stockholders
-233,107.0000
-276,126.0000
-228,302.0000
-340,141.0000
-306,620.0000
Diluted NI Available to Com Stockholders
-233,107.0000
-276,126.0000
-228,302.0000
-340,141.0000
-306,620.0000
Basic EPS
-2.12
--
-2.24
-3.63
-4.15
Diluted EPS
-2.12
--
-2.24
-3.63
-4.15
Basic Average Shares
115,066.5000
--
101,990.0000
93,670.0000
73,973.0000
Diluted Average Shares
115,066.5000
--
101,990.0000
93,670.0000
73,973.0000
Total Operating Income as Reported
-232,235.0000
-276,006.0000
-280,513.0000
-340,462.0000
-309,052.0000
Total Expenses
266,939.0000
284,579.0000
344,086.0000
360,802.0000
309,052.0000
Net Income from Continuing & Discontinued Operation
-233,107.0000
-276,126.0000
-228,302.0000
-340,141.0000
-306,620.0000
Normalized Income
-233,107.0000
-276,126.0000
-278,539.0000
-340,141.0000
-306,620.0000
Interest Income
4,228.0000
5,426.0000
3,059.0000
367.0000
2,447.0000
Interest Expense
5,102.0000
5,285.0000
373.0000
--
--
Net Interest Income
-874.0000
141.0000
2,686.0000
367.0000
2,447.0000
EBIT
-227,988.0000
-270,826.0000
-227,917.0000
-340,462.0000
-309,052.0000
EBITDA
-222,982.0000
-265,997.0000
-222,264.0000
-331,117.0000
-300,720.0000
Reconciled Cost of Revenue
10,655.0000
8,886.0000
--
--
--
Reconciled Depreciation
5,006.0000
4,829.0000
5,653.0000
9,345.0000
8,332.0000
Net Income from Continuing Operation Net Minority Interest
-233,107.0000
-276,126.0000
-228,302.0000
-340,141.0000
-306,620.0000
Total Unusual Items Excluding Goodwill
--
--
50,237.0000
--
--
Total Unusual Items
--
--
50,237.0000
--
--
Normalized EBITDA
-222,982.0000
-265,997.0000
-272,501.0000
-331,117.0000
-300,720.0000
Tax Rate for Calcs
0.0004
--
--
--
--
12/31/2020 - 10/16/2014

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

KPTI Karyopharm Therapeutics Inc.
1.1300
+3.67%
 
FGEN FibroGen, Inc.
1.1900
+0.85%
 
ALLO Allogene Therapeutics, Inc.
2.9800
+0.68%
 
ALLK Allakos Inc.
1.1850
-0.42%
 
SGMO Sangamo Therapeutics, Inc.
0.5801
+2.15%
 
GTHX G1 Therapeutics, Inc.
4.6900
+0.86%
 
APLT Applied Therapeutics, Inc.
4.4000
-5.17%
 
TCBP TC Biopharm (Holdings) Plc
1.1200
-2.61%
 
FATE Fate Therapeutics, Inc.
4.2400
+0.47%
 
BCAB BioAtla, Inc.
3.0000
+14.94%